The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
so just like the negative comments on here would ask you to second guess.
I ask you now to second guess all posts here - all information you have:
Who would be better equipped to make an investment decision on facts available? An institutional investor or a faceless bb poster.
And if institutional investors have been adding instead of selling. Then all the more this price action is resultant of a trading pattern
Wul - my take is that they employed all the right people and measures to get as accurate as possible a guidance.
This, from all data shared on here for verification by each investor, points currently to greater than baseline.
Just yesterday BBN shared a series of posts with reference to what we know on the subject.
The transformation program undertaken is designed to take the plant from current capacity of 2850-3000 upward.
So just perhaps investors are reading the delay wrong. Perhaps positive implementation has caused for further positive revision of guidance
Endion - it truly is something else this market.
I agree with BBN - the minute to minute sp movement should not be the concern here.
There are far greater plans in the making
But with this level of non company related volatility - it is discouraging to new investors, surely, looking at the Bushveld story
Paludina - I see the shipment data updated - Good news
Another 56t delivered at 72$ / kg. $4m in revenue.
I would invite other calculations but that seems like production is definitely up.
https://thebushveldperspective.com/blog/public-articles-1/post/nitrovan-shipments-to-the-us-183
Raz10 - I noticed the same
Rebar market in China:
China’s rebar price resumes climb-up, market robust
https://www.mysteel.net/article/5006477-05030101/DAILY--Chinas-rebar-price-resumes-climb-up--market-robust.html